An aerosolized dual-action autotaxin inhibitor-PPARγ agonist for the treatment of pulmonary fibrosis.

Although the decrease of BALF soluble collagen ( Figure S4 K) and lung tissue Col1a1 mRNA levels ( Figure S4 L) did not reach statistical significance following compound 5 administration, histological analysis revealed fewer fibrotic regions and decreased collagen deposition as evaluated with H&E and fast green/Sirius red staining ( Figures S4 M and S4N).

also in 111,027 other papers